A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the safety and efficacy of Tarceva monotherapy in patients
with advanced non-small cell lung cancer. Patients will receive Tarceva 150mg p.o. daily. The
anticipated time on study treatment is until disease progression, and the target sample size
is 100-500 individuals.